Cas:20493-41-8 quinapyramine manufacturer & supplier

We serve Chemical Name:quinapyramine CAS:20493-41-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

quinapyramine

Chemical Name:quinapyramine
CAS.NO:20493-41-8
Synonyms:quinapyramine
Molecular Formula:C17H22N6++
Molecular Weight:310.39700
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:84.72000
Exact Mass:310.19100
LogP:2.64400

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like quinapyramine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,quinapyramine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,quinapyramine Use and application,quinapyramine technical grade,usp/ep/jp grade.


Related News: The injection has previously proven to be as effective as standard daily pills with three active ingredients when administered monthly and also once every two months. quinapyramine manufacturer Right now, midstage data for Roche-AC Immune’s anti-tau antibody semorinemab in moderate Alzheimer’s are expected later this year, but it has already failed a phase 2 study in mild disease. quinapyramine supplier Russia, which had temporarily stopped issuing work visas to Chinese citizens, is also halting visa-free entry for Chinese tour groups, the government said. Moscow has also stopped issuing electronic tourist visas to individual Chinese travelers. quinapyramine vendor China is fast-tracking approval for innovative drugs at home in a bid to offer more and cheaper options to patients, as many in the rapidly aging country struggle to find alternatives to costly treatments sold by multinational pharmaceutical firms for chronic diseases. quinapyramine factory China is fast-tracking approval for innovative drugs at home in a bid to offer more and cheaper options to patients, as many in the rapidly aging country struggle to find alternatives to costly treatments sold by multinational pharmaceutical firms for chronic diseases.